secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001193125-23-056363
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q4 net loss $54.5M; VGX-3100 Phase 3 trial fails primary endpoint in biomarker group
--------------------------------------------------------------------------------

- Net loss of $54.5M ($0.22 per share) for Q4 2022; full year net loss $279.8M ($1.17 per share).
- Cash and short-term investments $253M as of Dec 31, 2022; cash runway projected into Q1 2025.
- REVEAL2 Phase 3 trial of VGX-3100 did not meet primary endpoint in biomarker-selected population (p=0.115); but achieved statistical significance in all-participants population (p=0.001).
- Positive Phase 1/2 data for INO-3107 in RRP: median decrease of 3 surgical interventions; 91% of patients saw reduction.
- Positive Phase 1b data for INO-4201 as Ebola booster: 100% of treated participants boosted humoral responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/0001193125-23-056363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/d378213d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-056363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer